Through these comprehensive datasets, we find that PRAD and NEPC tumors display a high degree of phenotypic heterogeneity with an array of androgen receptor (AR) positive and negative and NEPC gene regulatory networks (GRNs). The gene discussed is AR; the disease is prostate adenocarcinoma.